Lynce, Filipa http://orcid.org/0000-0001-6615-7076
Wang, Hongkun
Petricoin, Emanuel F.
Pohlmann, Paula R.
Smaglo, Brandon
Hwang, Jimmy
He, Aiwu R.
Subramaniam, Deepa S.
Deeken, John
Marshall, John
Pishvaian, Michael J.
Funding for this research was provided by:
Millenium (N/A)
National Cancer Institute (P30CA051008)
Novartis Pharma (N/A)
Article History
Received: 21 June 2019
Accepted: 28 August 2019
First Online: 19 September 2019
Compliance with ethical standards
:
: FL has received research grants from BMS, Pfizer, Genentech/Roche, Immunomedics, Calithera, Chugai, Regeneron, Tesaro and Inivata; has participated in advisory boards (non-paid) with BMS, Jounce and AstraZeneca and travel expenses from BMS, Genentech and Jounce. EFP has a leadership role in Ceres Nanosciences and Perthera; has stock and other ownership interests in Avant Diagnostics, Ceres Nanosicences and Perthera; has consulting or advisory roles with Avant Diagnostics, AZGen, Ceres Nanosciences and Perthera; has received research funding from Abbvie, Ceres Nanosciences, GSK and Symphogen; has intellectual property rights in NIH Patents Licensing Fee Distribution/Royalty and University assigned patent licensing fee/royalty; has received travel expenses by Ceres Nanoscience and Perthera. PRP has intellectual property rights (United States Patents no. 8,486,413; no. 8,501,417; 9,023,362 and 9,745,377: Immunological Compositions as Cancer Biomarkers and/or Therapeutics); has ownership interests in Immunonet BioSciences; has consulted for Heron, Personalized Cancer Therapy, PUMA, Pfizer, Oncoplex Dx, CARIS, Sirtex; has received financial support for educational programs (non-CME teaching) from ASCO, Dava Oncology, Roche; has received research grants to the institution from Immunonet BioSciences, Genentech/Roche, Pfizer, Cascadian therapeutics/Seattle Genetics, Fabre-Kramer, Advanced Cancer Therapeutics, Pieris. BS has received honoraria for speaking for TAIHO. DSS is an employee and has stock and other ownership interests in AZ; DSS was on speakers’ bureau for AZ and Genentech until June 2019. JD has received research grants from Merck, BMS and Loxo Oncology and has outside income/royalties from UpToDate. JM has been a speaker/consultant and received honoraria from Genentech, Amgen, Celgene, Taiho, Bayer, Merck, Caris and Indivumed. MP has been a speaker/consultant for AstraZeneca/MedImmune, Caris Life Sciences, Celgene, Merrimack, Perthera, RenovoRx and Sirtex Medical; has received travel, accommodations and expenses Support from AstraZeneca/MedImmune, Merck, Caris Life Sciences, Perthera and Sirtex Medical and has Stock interests in Perthera.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.